Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Conditions
- Angioimmunoblastic T-cell Lymphoma
- B-cell Childhood Acute Lymphoblastic Leukemia
- B-cell Chronic Lymphocytic Leukemia
- Childhood Burkitt Lymphoma
- Childhood Diffuse Large Cell Lymphoma
- Childhood Grade III Lymphomatoid Granulomatosis
- Childhood Immunoblastic Large Cell Lymphoma
- Childhood Nasal Type Extranodal NK/T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Intraocular Lymphoma
- Noncutaneous Extranodal Lymphoma
- Peripheral T-cell Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hairy Cell Leukemia
- Small Intestine Lymphoma
- T-cell Childhood Acute Lymphoblastic Leukemia
- T-cell Large Granular Lymphocyte Leukemia
- Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
- DRUG: oxaliplatin
- DRUG: etoposide
Sponsor
National Cancer Institute (NCI)